Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect Treace Medical Concepts to post earnings of ($0.31) per share and revenue of $52.07 million for the quarter.
Treace Medical Concepts Stock Down 1.1 %
Shares of Treace Medical Concepts stock traded down $0.08 during trading on Friday, reaching $7.26. The company's stock had a trading volume of 425,844 shares, compared to its average volume of 752,098. Treace Medical Concepts has a 1-year low of $3.92 and a 1-year high of $11.33. The company has a 50-day simple moving average of $7.76 and a two-hundred day simple moving average of $7.88. The company has a quick ratio of 2.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.51. The company has a market cap of $456.58 million, a price-to-earnings ratio of -7.33 and a beta of 0.77.
Analyst Upgrades and Downgrades
A number of research firms recently commented on TMCI. BTIG Research upgraded shares of Treace Medical Concepts from a "neutral" rating to a "buy" rating and set a $16.00 target price for the company in a research note on Tuesday, February 4th. Truist Financial cut their target price on Treace Medical Concepts from $9.50 to $8.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $9.93.
Check Out Our Latest Report on TMCI
Insider Activity
In related news, insider Sean F. Scanlan sold 50,000 shares of Treace Medical Concepts stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $7.97, for a total transaction of $398,500.00. Following the completion of the transaction, the insider now directly owns 364,081 shares in the company, valued at approximately $2,901,725.57. This trade represents a 12.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 27.72% of the company's stock.
About Treace Medical Concepts
(
Get Free Report)
Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.
Further Reading
Before you consider Treace Medical Concepts, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Treace Medical Concepts wasn't on the list.
While Treace Medical Concepts currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
